This week, Calico’s chief executive Art Levinson revealed that he is beginning to recruit a superstar genetics team.
“What we are developing at GenapSys will enable the genomic revolution not only for healthcare, but for a wide range of applications,” said Dr. Hesaam Esfandyarpour, GenapSys founder and chief executive.
This week, a District Court judge in California struck down a patent held by a San Diego-based diagnostics company called Sequenom. The judge ruled that a “natural phenomenon” could not be patented.
Editor’s Pick VentureBeat caught up with some of Silicon Valley’s power players to gauge their opinions on Google’s new initiative to prolong human life.
SynapDx has earned the support of venture capitalists and geneticists alike, raising $15.4 million to develop a blood test for autism.
“Imagine all diagnostics some day being reduced to a simple blood test,” said CEO Roopam Banerjee, who believes Raindance products are a “step in that direction.”
The goal for the multiyear partnership is to make genetic analysis a routine part of patient care.
Should human genes be patented? The Supreme Court is weighing in today in a landmark case that will have an enormous impact on the future of science, technology and medicine.
Third Rock is a venture capital fund solely dedicated to health care companies. The firm’s distinct hands-on approach first discovers breakthrough technology and then builds the teams to execute it.
This startup uses a semiconductor-based, single-molecule platform for genomic analysis — and that’s worth $20 million to a group of investors.
Editor’s Pick Futurist and entrepreneur Michael Vassar has a bone to pick with the U.S. medical system. He hopes to “humiliate” it into providing better quality care by creating a “product that works better than the system.”
Bina’s platform significantly reduces the time and cost of processing the human genome, which has far-reaching implications for the world of healthcare.
The cost of sequencing the human genome has plummeted. But how will this benefit doctors and patients?
A new cancer discovery puts the emerging field of genomics on the map, may speed up the drug approval process, and de-risks groundbreaking research for venture-funded biotech companies.
Here’s an API launch that won’t leave you yawning: 23andme is opening up its treasure trove of genetics data to third-party developers.
You may not think music is in your genes, but a new lab from 23andMe may just prove you wrong.
Scientists at Stanford University and the J. Craig Venter Institute — remember the Human Genome project — have simulated an entire organism in software for the first time ever.
Guest Post The cost of sequencing the human genome continues to fall, reaching a low of $1,000 this year due to a new microchip and machine designed by genetics company Life Technologies Corp. And unleashed by those lower costs, a small cadre of entrepreneurs in Silicon Valley is exploring ways to harness this data to enable us to live longer and healthier lives.
More genetic links for breast cancer – Whole-genome association studies that tease out links between minute genetic variations and the likelihood of disease are definitely building momentum. Over the last several days, researchers reported six new variations that increase the risk of breast cancer for women who have inherited them. (For background, see this Boston Globe piece or my recent take on the subject.) It’s now conceivable that scientists may soon have an excellent handle on the genetic contributions to this particular disease.
Scientists yesterday reported finding seven new gene variants linked to diabetes, a sign that the disease-gene hunt may have finally attained a sort of critical momentum.